AstraZeneca gains CDSCO approval for treatment of muscle-invasive bladder cancer
Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Durvalumab as adjuvant…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
durvalumab
MRP of 3 anti-cancer drugs to come down due to exemption from custom duty and reduction in GST
NPPA has issued an OM directing the concerned manufacturers to reduce the maximum retail price on Trastuzumab, Osimertinib and…
AstraZeneca India receives CDSCO approval for Durvalumab for specified additional indication
Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is…
Decoding Budget 2024-25: A lacklustre budget for pharma
The Finance Minister announced the Budget for 2024-25 on July 23, during the Monsoon Session of Parliament
AstraZeneca gets CDSCO approval for Tremelimumab combination in India
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma…
AstraZeneca’s Durvalumab gets CDSCO nod to treat locally advanced or metastatic biliary tract cancer
The approval for AstraZeneca molecule is based on the findings of TOPAZ-1, a Phase-3 global clinical trial with patients recruited…
EU approves AstraZeneca’s Imfinzi for treatment of extensive-stage small cell lung cancer
Imfinzi, in combination with etoposide and either carboplatin or cisplatin, is also approved in the US, Japan and several other…